TIGIT and neoplasm: To assess the anti-tumor activity of the oncolytic VV in vivo, 4T1 tumor-bearing BALB/c mice were treated with PBS, VV-Control, or VV-α-TIGIT every other day for 3 times via intratumoral injection (Fig. 4A).